Live feed14:29:00·752dPRReleasevia QuantisnowIvonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in ChinaByQuantisnow·Wall Street's wire, on your screen.SMMT· Summit Therapeutics Inc.Health Care
